Clinical significance of acute neurohormonal response after levosimendan treatment

被引：15
作者：
Giannakoulas, George
Giannoglou, George
Vassilikos, Vasilis
Martiadou, Kostantina
Kalpidis, Panagiotis
Parharidis, George
Louridas, George
机构：
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2006年 / 98卷 / 08期
关键词：
D O I：
10.1016/j.amjcard.2006.07.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1123 / 1124
页数：2
相关论文
共 9 条
[1]   Effects of Levosimendan versus Dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure [J].
Adamopoulos, Stamatis ;
Parissis, John T. ;
Iliodromitis, Efstathios K. ;
Paraskevaidis, Ioannis ;
Tsiapras, Dimitrios ;
Farmakis, Dimitrios ;
Karatzas, Dimitrios ;
Gheorghiade, Mihai ;
Filippatos, Gerasimos S. ;
Kremastinos, Dimitrios T. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (01) :102-106
[2]   The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine [J].
Avgeropoulou, C ;
Andreadou, I ;
Markantonis-Kyroudis, S ;
Demopoulou, M ;
Missovoulos, P ;
Androulakis, A ;
Kallikazaros, I .
EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (05) :882-887
[3]   Time course of B-Type natriuretic peptide (BNP) and N-terminal ProBNP changes in patients with decompensated heart failure [J].
Gegenhuber, A ;
Mueller, T ;
Firlinger, F ;
Lenz, K ;
Poelz, W ;
Haltmayer, M .
CLINICAL CHEMISTRY, 2004, 50 (02) :454-456
[4]   Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients [J].
Kyrzopoulos, S ;
Adamopoulos, S ;
Parissis, JT ;
Rassias, J ;
Kostakis, G ;
Iliodromitis, E ;
Degiannis, D ;
Kremastinos, DT .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 99 (03) :409-413
[5]   High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure [J].
Maeda, K ;
Tsutamoto, T ;
Wada, A ;
Mabuchi, N ;
Hayashi, M ;
Tsutsui, T ;
Ohnishi, M ;
Sawaki, M ;
Fujii, M ;
Matsumoto, T ;
Kinoshita, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (05) :1587-1593
[6]   Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide [J].
McLean, AS ;
Huang, SJ ;
Nalos, M ;
Ting, I .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 46 (06) :830-835
[7]   Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure [J].
Moertl, D ;
Berger, R ;
Huelsmann, M ;
Bojic, A ;
Pacher, R .
EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (07) :1156-1163
[8]   Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure [J].
Mueller, T ;
Gegenhuber, A ;
Haltmayer, M .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 104 (03) :355-356
[9]   Effects of Levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure [J].
Parissis, JT ;
Panou, F ;
Farmakis, D ;
Adamopoulos, S ;
Filippatos, G ;
Paraskevaidis, I ;
Venetsanou, K ;
Lekakis, J ;
Kremastinos, DT .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (03) :423-426
1